Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (20): 3715-3718.doi: 10.3969/j.issn.1673-8225.2011.20.025

Previous Articles     Next Articles

Effects of brucine on apoptosis of multiple myeloma cell line U266 and bax gene expression

Li Zhi-hua, Ma Yan-ping, Wang Yi-hua, Feng Jing, Li Ling-fei   

  1. Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
  • Received:2010-11-19 Revised:2011-01-09 Online:2011-05-14 Published:2011-05-14
  • Contact: Ma Yan-ping, Doctor, Chief physician, Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China yanpingma@hotmail.com
  • About author:Li Zhi-hua★, Studying for master’s degree, Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China lizhihuasx@163.com
  • Supported by:

    the Item of Shanxi Scholarship Council of China, No. (2008)10-99*

PDF

465

Abstract:

BACKGROUND: Brucine has anti-tumor effect. However, its influence on growth of multiple myeloma cells is not clear.
OBJECTIVE: To investigate apoptotic mechanism of brucine on human multiple myeloma.
METHODS: Logarithmic growth phase of U266 cells were treated with 0, 0.05, 0.1, 0.2, and 0.4 g/L brucine for 12, 24, and 48 hours, measured IC50 by MTT, and interfere the U266 cells. The apoptotic effect of brucine on human multiple myeloma cell line-U266 was observed by morphological observation and RT-PCR.
RESULTS AND CONCLUSION: Brucine induced U266 apoptosis showed a time- and concentration-dependent manner (P < 0.05). The IC50 level was 0.16 g/L at 48 hours after intervention. Apoptotic body could be found in brucine treated-apoptotic cells, meantime, the expression of pro-apoptosis gene bax was gradually increased with time prolonged (P < 0.01). It is suggest that 0.4 g/L concentration brucine induced U266 apoptosis, and the effect showed in a concentration- and time-dependent manner, which possibly through the activation of bax pathway.

CLC Number: